The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles

• Status: Recruiting
• Trial end date: 2022-08-15
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to test the hypothesis that addition of daily small dose of human menopausal gonadotropin (HMG) drug following oocytes retrieval could improve the fertility outcome in women undergoing in-vitro fertilization

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Menotropins

Criteria

Inclusion Criteria:

• Females undergoing Intra-Cytoplasmic Sperm Injection (ICSI) cycles

• Age between 20 and 40 years

Exclusion Criteria:

• Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved)